- Phase 3 FUZION study (NCT05347095) randomized patients 2:2:1 to TREMFYA 100 mg q8w, 200 mg q4w, or placebo after IV induction.
Phase 3 FUZION data: TREMFYA maintained or improved combined fistula remission through 48 weeks, with 35% remission in the 100mg q8w group at Week 48 vs 28% at Week 24. Only IL-23 to show efficacy in a dedicated placebo-controlled trial for perianal fistulizing Crohn's.
One free account opens every story complete, the live board, the 30-day calendar, a watchlist and breaking alerts on your phone. No card. The wire stays free to read.